Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
2.470
-0.110 (-4.26%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.

Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.

The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.

The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020.

The company is headquartered in Rehovot, Israel.

Purple Biotech Ltd
Purple Biotech logo
Country Israel
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 20
CEO Gil Efron

Contact Details

Address:
4 Oppenheimer Street, Science Park
Rehovot, 7670104
Israel
Phone 972 3 933 3121
Website purple-biotech.com

Stock Details

Ticker Symbol PPBT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001614744
CUSIP Number 74638P109
ISIN Number US74638P1093
SIC Code 2834

Key Executives

Name Position
Gil Efron CPA, M.A. Chief Executive Officer
Dr. Michael Schickler Ph.D. Head of Clinical and Regulatory Affairs
Ido Morpurgo B.Sc., L.L.M. Vice President of Operations

Latest SEC Filings

Date Type Title
Nov 15, 2024 6-K Report of foreign issuer
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 6-K Report of foreign issuer
Oct 25, 2024 6-K Report of foreign issuer
Oct 10, 2024 6-K Report of foreign issuer
Oct 9, 2024 6-K Report of foreign issuer
Oct 2, 2024 6-K Report of foreign issuer
Sep 18, 2024 6-K Report of foreign issuer
Sep 11, 2024 6-K Report of foreign issuer
Aug 19, 2024 6-K Report of foreign issuer